Proposed Fundraising via Placing

AI SummaryClose X

Verici Dx plc is proposing an equity fundraising to raise approximately £2.5 million in gross proceeds through a placing of new ordinary shares at 0.35 pence per share, representing a 17.6% discount to its previous closing mid-price. The funds will support the commercial scale-up of next-generation blood-based tests for the kidney transplant market, with the company's lead product, Tutivia™, having generated $3.0 million in revenue in FY25 and being used in 29 US ordering centers. The fundraising includes a minimum of 700 million placing shares, representing at least 47% of existing share capital, and a separate retail offer aiming to raise up to an additional £0.2 million. The company anticipates needing further equity funding within 12 months and is seeking shareholder approval for allotment and pre-emption rights disapplication. Admission of the placing shares to AIM is expected on June 23, 2026.

Disclaimer*

Companies

Verici DX (VRCI)
UK 100

Latest directors dealings